Pakistan’s drug regulator wants to hear from you when a medicine causes an unexpected reaction — and now it is asking in Sindhi. The Drug Regulatory Authority of Pakistan (DRAP) has released an animated video in the Sindhi language that walks patients and healthcare professionals through how to report suspected side effects of medicines.
The video was produced by DRAP’s National Pharmacovigilance Centre (NPC), the federal body responsible for collecting and analysing reports of adverse drug events across the country. In simple, everyday language, it explains the different channels through which a suspected reaction can be reported — both to the Provincial Pharmacovigilance Centre in Sindh and to the NPC at the national level.
Key Takeaways
- DRAP’s National Pharmacovigilance Centre has released an animated video in Sindhi explaining how patients and healthcare professionals can report suspected medicine side effects.
- Reports can be filed through DRAP’s online e-reporting system, the NPC phone line and email, a doctor or pharmacist, or the medicine’s manufacturer.
- Anyone can report — patients, carers and health workers — and you do not need to prove the medicine caused the reaction before filing.
Why a Sindhi-language video matters
Sindh is home to tens of millions of Sindhi speakers, a large share of whom interact with doctors, pharmacies and hospitals in their mother tongue. When official health information exists only in English or Urdu, a practical barrier forms: people who experience a bad reaction to a medicine may never learn that there is a formal system for reporting it, let alone how to use it.
That gap has real consequences. Under-reporting of adverse drug reactions is a well-documented challenge in health systems around the world, and Pakistan is no exception. Pharmacovigilance — the ongoing monitoring of medicine safety after drugs reach the market — depends entirely on reports filed from the field. If entire communities are effectively cut out of the reporting system by a language barrier, the safety data that regulators rely on becomes less representative, and safety signals emerge more slowly.
By producing the explainer in Sindhi, DRAP is acknowledging something straightforward: effective safety reporting requires speaking to people in the language they actually use, especially in healthcare settings where confusion can be costly. The animated format goes a step further, making the content accessible to viewers with varying levels of health literacy.
What the video explains: the reporting channels
The core of the video is a walkthrough of how an ordinary person or health worker can get a suspected side-effect report to the right desk. DRAP accepts reports through several channels:
- Online e-reporting system — DRAP’s Med Vigilance E-Reporting System (available at vigiflow-eforms.who-umc.org/pk/adr), with forms offered in English and Urdu. This is the channel DRAP now recommends for direct public reporting.
- Phone — the National Pharmacovigilance Centre can be reached on 051-9255981 during working hours (9 am to 5 pm on working days).
- Email — reports and queries can be sent to npc@dra.gov.pk.
- Through your doctor or pharmacist — DRAP’s first advice is to tell your treating doctor or pharmacist. They can assess the reaction in person and file it on the yellow reporting form used by health workers.
- Through the manufacturer — the company that makes the medicine is another accepted route for a report.
The video encourages healthcare professionals and the public alike to familiarise themselves with these mechanisms and to report any suspected adverse event rather than staying silent about it.
Who can report — and what counts as reportable
One point worth stressing, because it surprises many people: you do not need a doctor’s permission to file a report, and you do not need to be certain the medicine caused the problem. DRAP accepts reports from patients, carers, relatives and health workers alike.
A “suspected adverse event” covers a wide range of experiences — a rash that appears two days after starting a new antibiotic, swollen lips after a painkiller, persistent vomiting in a child after a syrup, unusual dizziness, or anything else that seems wrong after taking a medicine. The regulator’s analysts, not the reporter, are the ones who assess whether a pattern is emerging. Your job is simply to describe what happened, which medicine was involved, and when.
A practical tip: keep the medicine’s pack if you can. The product name, batch number, manufacturing and expiry dates all help the regulator trace the report accurately.
A side effect is not the same as a bad product
It helps to know that DRAP treats different kinds of medicine problems through different channels — and mixing them up can slow things down.
If the medicine itself looks wrong — tablets that crumble oddly, a cloudy syrup, a pack that seems tampered with or fake — that is a quality defect, not a side effect. DRAP handles those through a separate product quality defect form, which asks for the batch number, expiry date and where you bought the medicine, and keeps the physical pack available where possible so it can be sent for laboratory testing.
Similarly, if a medicine has disappeared from pharmacy shelves, that is a shortage issue, reported to DRAP’s toll-free line 0800-03727 or by email at drugshortages@dra.gov.pk. Knowing which door to knock on means your report reaches the team that can actually act on it.
Why your report actually changes things
It is easy to assume a single report disappears into a bureaucracy. In pharmacovigilance, the opposite is closer to the truth. Adverse-event data collected from patients and healthcare professionals is what allows regulators to spot unexpected side effects, judge whether risks are growing at scale, and take corrective action — from updating a medicine’s warning label and issuing safety communications to withdrawing a product from the market.
The more representative and geographically diverse the reporting base, the more reliable the safety signal. Regulatory actions around the world routinely begin with reports filed by ordinary patients who noticed something wrong and said so. Community-level outreach in regional languages is therefore not just a communications nicety — it is a direct contributor to the quality of drug-safety outcomes at the national level.
The bigger picture: health information in Pakistan’s languages
DRAP’s Sindhi video fits into a broader pharmacovigilance awareness drive, but it also points to a larger principle: public-health communication in Pakistan works best when it meets people where they are. Animation, regional languages and mobile-friendly formats travel easily over WhatsApp and social platforms that are widely used across Sindh’s cities, towns and villages.
If the approach succeeds, it would be natural to expect similar explainers in other regional languages — Punjabi, Pashto and Balochi speakers face the same language gap in their dealings with the health system. For now, patients and healthcare workers in Sindh have one fewer excuse to stay quiet when a medicine misbehaves. Watch the video, learn the channels, and report: it is how medicines get safer for everyone.